Piper Sandler analyst David Westenberg has initiated coverage on Veracyte Inc with an Overweight rating and announced a price target of $66. Veracyte shares closed at $56.62 on Tuesday. This new recommendation contrasts with a recent outlook from Morgan Stanley, where analyst Tejas Savant maintained an Underweight rating while raising the price target to $47 from $37. Veracyte trades on the NASDAQ under the ticker symbol VCYT.

Analyst Ratings and Price Targets

The initiation by Piper Sandler provides a bullish perspective on the company's future performance. Meanwhile, Morgan Stanley's revised valuation acknowledges potential upside but maintains a cautious stance relative to broader market peers.

The divergence in ratings highlights differing views on Veracyte's risk-reward profile. Investors should consider the varying price targets and recommendations when evaluating their positions in the genomic diagnostics company.

Veracyte, Inc. will release its financial results for the second quarter of 2026 after the market closes on Thursday, July 30, 2026. The company, a global diagnostics firm focused on cancer care, scheduled the announcement to provide investors with an update on its performance. Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results and offer a general business update.

The conference call will be webcast live from the company’s website. Investors can access the live broadcast via the provided link. A replay of the webcast will be available following the conclusion of the live event and will be accessible on the company’s investor relations website.

Conference Call Details

Veracyte’s portfolio includes molecular tests designed to assess tumor biology and assist clinicians in cancer care decisions. The company utilizes a diagnostics platform combining genomic data, bioinformatics, and AI to support its product pipeline.